|Bid||0.00 x 3200|
|Ask||0.00 x 1800|
|Day's Range||62.29 - 63.74|
|52 Week Range||57.41 - 77.91|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||26.18|
|Earnings Date||Jan 25, 2019|
|Forward Dividend & Yield||1.68 (2.63%)|
|1y Target Est||62.88|
Jim Cramer zooms through his take on callers' favorite stocks, including a consumer goods play that's down on its luck.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 7% during October and average hedge fund losing about 3%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by about […]
The majority of Wall Street analysts providing recommendations on Procter & Gamble (PG) stock maintain a neutral outlook. Wall Street expects near-term cost headwinds and unfavorable currency rates to hurt the company’s net sales and EPS growth rate. However, innovation-driven products, productivity savings, and a lower effective tax rate are projected to support the top and bottom lines.
Procter & Gamble (PG) has impressed with its earnings despite facing strong sales and margin headwinds in the recent past. The company outperformed analysts’ estimates in the past 14 quarters with an average positive surprise of 4.3%, which is impressive. Focus on productivity and cost savings, a considerable decline in the effective tax rate, and share repurchases have helped the company to surpass analysts’ expectations.
Procter & Gamble (PG) announced price increases across several product categories aimed at offsetting the adverse impact from the foreign exchange rate and continued inflation in commodities. However, we expect the company’s margins to remain weak and continue to slide, at least in the near term.
PG Stock Is Up 15.2% since Q1 Results: Will Uptrend Continue? The company’s organic sales came in better than what analysts expected and rose 4% thanks to the improvement in volumes across all business segments and the favorable mix in the beauty segment. Despite strong organic sales growth, Procter & Gamble’s net sales growth remained low, reflecting the adverse impact from the foreign exchange rate.
Procter & Gamble stock (PG) has seen a healthy recovery since the company reported stronger-than-expected first-quarter results on October 19. Procter & Gamble’s sales and earnings surpassed Wall Street’s expectations, and its 4% organic sales growth rate during the first quarter of fiscal 2019 impressed investors. Higher volumes across all business segments and its positive mix in the beauty segment supported the company’s organic sales growth.
NEW YORK, Nov. 12, 2018 /PRNewswire/ -- Every morning, 23 million Americans living with diabetes must make careful decisions to manage their daily living: what to eat, what to drink, how to exercise – and even what toothpaste to use.
Can someone please reset the algo? Yesterday I talked about how there are ETFs that mimic the way momentum managers think so you do not need to buy a whole bunch of stocks. It's autopilot investing.
Colgate-Palmolive President and Chief Operating Officer, Noel Wallace, will participate in a fireside chat at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, November 13, 2018 at 1:40 p.m.
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Wall Street analysts have a consensus target price of $61.79 per share on Church & Dwight (CHD) stock, which implies a downside of 6.5% based on its closing price of $66.06 on November 2.
Shares of Church & Dwight (CHD) have outperformed the benchmark index as well as its peers so far this year. Church & Dwight has managed to generate stellar sales and earnings growth at a time when most leading household and personal care product manufacturers in North America are struggling to defend their market shares. Church & Dwight’s strong portfolio of value and premium brands, its focus on innovation-led products, its export expansion, and the benefits it’s garnered from strategic acquisitions are driving its top line, which has risen at an average rate of 12.9% in the past four quarters.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he likes Biogen Inc's (NASDAQ: BIIB ) management, but he doesn't like the hype around the new Alzheimer drug. People don't want to own ...
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Colgate-Palmolive Co. CL : "Colgate did not have a good quarter and there were a lot of people who downgraded it.
Clorox (CLX) reported stronger-than-expected results for the first quarter of fiscal 2019—the period ending on September 30. The company’s top line beat analysts’ estimate and improved 4% on a YoY (year-over-year) basis due to the acquisition, higher pricing, and improved volumes. However, divestiture and negative currency rates remained a drag.
Church & Dwight (CHD) is outperforming its peers so far this year and has handily exceeded Wall Street’s expectations for the past several quarters both on the sales and earnings fronts. On the contrary, Church & Dwight has grown its sales and earnings at a double-digit rate, which is impressive. During the first two quarters of 2018, Church & Dwight’s top line increased 14.7% and 14.5%, respectively, and surpassed analysts’ estimate.
Colgate-Palmolive’s (CL) net sales in North America jumped 8.0% during the third quarter driven primarily by skin care acquisitions, which contributed 6.0% to top-line growth. The segment’s organic sales also improved 2% led by a 1.5% increase in organic volumes and a 0.5% increase in pricing.
Colgate-Palmolive (CL) reported net sales of $3.8 billion during the third quarter, which fell short of analysts’ estimate and decreased 3.0% YoY. Adverse currency rates had a negative impact of 4.0% on the top line. Meanwhile, volumes remained weak. The company managed to improve pricing by 1.0%, but that wasn’t enough to offset the negatives.
JPMorgan's Andrea Teixeira downgraded Colgate-Palmolive from Neutral to Underweight with a price target lowered from $61 to $54. There's reason to be bearish into the fourth quarter, Teixeira said in a note. Specifically, management's guidance for the quarter implies a low-single-digit organic sales growth but this is only likely to play out if pricing can improve sequentially.